Long-term use of everolimus as a component of immunosuppressive therapy in liver transplant recipients

QR Code

Long-term use of everolimus as a component of immunosuppressive therapy in liver transplant recipients

This article presents a three-year experience with mTOR inhibitors in the schemes of immunosuppressive therapy in patients post liver transplantation.

Saved in:

Bibliographic Details
Main Authors:	M. Sh Khubutia, V. E. Sjutkin, N. K. Kuznetsova, S. V. Zhuravel, M. S. Novruzbekov
Format:	Article
Language:	English
Published:	N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department 2016-01-01
Series:	Трансплантология (Москва)
Subjects:	liver transplantation immunosuppressive therapy inhibitors mtor
Online Access:	https://www.jtransplantologiya.ru/jour/article/view/13
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Changes in glomerular filtration rate in liver recipients after reduced exposure to calcineurin inhibitors with concomitant everolimus administration within the first year after immunosuppression conversion
by: V. E. Syutkin, et al.
Published: (2022-01-01)

The effect of early everolimus administration on the renal function while reducing the dosage of calcineurin inhibitors in liver transplant recipients in a long-term follow-up
by: V. E. Syutkin, et al.
Published: (2021-06-01)

Conversion to everolimus to preserve kidney function in a heart transplant recipient, a personalized approach of immunos uppressive therapy
by: N. N. Koloskova, et al.
Published: (2018-09-01)

Complete regression of generalized plasmacytoma of lymph nodes in a liver transplant recipient during the conversion of immunosuppressive therapy from tacrolimus to everolimus
by: V. E. Syutkin, et al.
Published: (2021-09-01)

The role of immunotolerance in immunosuppressive therapy after liver transplantation
by: E. Yu. Anosova, et al.
Published: (2024-09-01)

Analysis of early use of everolimus with low-dose calcineurin inhibitors in kidney transplant recipient
by: I. G. Kim, et al.
Published: (2019-10-01)

EVEROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS
by: E. I. Prokopenko
Published: (2010-06-01)

THE MODERN IMMUNOSUPPRESSIVE TACTICS AS A WAY FOR INDUCING OF TOLEROGENIC STRATEGY AFTER LIVER TRANSPLANTATION (ANALYSIS OF THE PROBLEM STATUS)
by: S. D. Artamonov, et al.
Published: (2012-05-01)

The experience of use of everolimus in patients having undergone to orthotopic liver transplantation
by: V. E. Syutkin, et al.
Published: (2018-08-01)

Features of lipid-lowering therapy in liver transplant recipients
by: A. A. Kucherov, et al.
Published: (2023-12-01)

Risk factors affecting the incidence of CMV infection in recipients after living donor liver transplantation
by: Mostafa Attya Elfors, et al.
Published: (2025-06-01)

Pharmacoeconomic analysis of everolimus immunosuppressive therapy for <i>de novo</i> kidney transplant recipients in Russia
by: N. A. Avxentyev, et al.
Published: (2019-05-01)

Treatment of hepatitis C in liver transplant recipients in the Moscow Center for Liver Transplantation within 10 years
by: M. Sh. Khubutia, et al.
Published: (2016-01-01)

Comparative analysis of induction immunosuppressive therapy protocols in renal transplant recipients (retrospective review)
by: Sh. R. Galeev, et al.
Published: (2020-07-01)

Extrahepatic malignancies in a liver transplant recipient from a living related donor
by: I. Yu. Kolyshev, et al.
Published: (2020-09-01)

Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy
by: I. G. Kim, et al.
Published: (2018-01-01)

Clinical course and outcomes of COVID-19 infection in liver transplant recipients: single-center cross-sectional study
by: S. E. Voskanyan, et al.
Published: (2022-03-01)

Clinical laboratory aspects of one-component immunosuppression during liver transplantation
by: M. Sh. Khubutia, et al.
Published: (2018-08-01)

Characteristics of Post-Transplant Lymphoproliferative Disorder in Adult Liver Transplant Recipients—A Single Centre Experience
by: Katrina Tan, et al.
Published: (2025-06-01)

BIOMARKERS OF IMMUNE TOLERANCE IN LIVER TRANSPLANTATION
by: O. P. Shevchenko, et al.
Published: (2016-11-01)

Risk Prediction and Management of BKPyV-DNAemia in Kidney Transplant Recipients: A Multicenter Analysis of Immunosuppressive Strategies
by: Jin-Myung Kim, et al.
Published: (2025-07-01)

Tolerance and minimization of immunosuppressive therapy after liver transplantation
by: O. A. Gerasimova, et al.
Published: (2021-09-01)

Aortic valve replacement for patient with infective endocarditis early after liver transplantation with a complete withdrawal of immunosuppressive therapy
by: S. F. Bagnenko, et al.
Published: (2017-12-01)

Progress in blood transfusion for liver transplantation
by: YU Xiaochao, et al.
Published: (2025-06-01)

Сlinical features of malignant tumors against the background of immunosuppressive therapy in heart transplant recipients
by: L. B. Krougly, et al.
Published: (2021-07-01)

An acute episode of rhabdomyolysis associated with everolimus and cabergoline intake in a postpartum kidney recipient
by: B. I. Yaremin, et al.
Published: (2017-12-01)

A case of rhabdomyolysis after atorvastatin therapy of a liver transplant recipient receiving immunosuppressive therapy with cyclosporine
by: A. V. Shabunin, et al.
Published: (2021-06-01)

PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION
by: M. V. Avxentyeva, et al.
Published: (2015-06-01)

Evaluation of Anxiety, Self-Management and Compliance with Immunosuppressive Therapy in Kidney Transplant Recipients
by: Aliye Bulut, et al.
Published: (2025-06-01)

POSTOPERATIVE COMPLICATIONS IN LIVER TRANSPLANT RECIPIENTS: MODERN СCONSIDERATIONS OF PATHOGENESIS AND MAIN AREAS OF PROPHYLAXIS AND TREATMENT
by: M. Sh. Khubutia, et al.
Published: (2009-05-01)

The role of calcineurin inhibitors in the progression of hepatocellular carcinoma after liver transplantation
by: O. D. Olisov, et al.
Published: (2022-09-01)

Oncological Complications of Liver Transplantation: A Narrative Review on De Novo and Donor-Transmitted Cancers
by: Tancredi Vincenzo Li Cavoli, et al.
Published: (2025-05-01)

Adverse effects of immunosuppressive therapy after kidney transplant
by: S. V. Popov, et al.
Published: (2025-03-01)

Treatment of the «intra-abdominal infection» after orthotopic liver transplantation (a case report)
by: M. Sh. Khubutia, et al.
Published: (2018-08-01)

Induction immunosuppression in kidney transplantation: Thymoglobulin® (a literature review)
by: A. V. Pinchuk
Published: (2016-02-01)

INFECTIONS IN THE INTENSIVE CARE UNIT FOLLOWING LIVER TRANSPLANTATION: PROFILE OF A SINGLE CENTER
by: E. Otan, et al.
Published: (2013-10-01)

Interactions between Immunosuppressive Therapy and Direct-Acting Antivirals in Kidney Transplant Recipient with Hepatitis C Infection
by: Paolo Carta, et al.
Published: (2020-05-01)

MEDICAMENTAL IMMUNOSUPRESSION IN EARLY AGE PEDIATRIC LIVER RECIPIENTS
by: S. V. Gautier, et al.
Published: (2012-09-01)

Successful liver transplantation in critically ill patient (Case report)
by: M. Sh. Khubutia, et al.
Published: (2016-01-01)

Related liver fragment transplantation for type 1 glycogenosis: the first Russian experience The paper describes two clinical examples of successful related liver fragment transplantation for type 1 glycogenosis in a one-year-old boy and a 6-year-old girl. The given first successful clinical experience suggests that liver fragments for type 1 glycogenoses can be transplanted from live related donors and offers promise for the radical treatment of patients with this pathology.
by: A. V. Filin, et al.
Published: (2018-08-01)